A double-blind switch study of XXXX and @entity906 in @entity3119 .

@entity1 @entity903 @entity3595 @entity750 @entity906 @entity3119
BACKGROUND: The treatment guidelines for @entity3119 ( @entity3119 ) propose to switch @entity750 reuptake inhibitors (SRIs) in case of refractoriness. However, no controlled research has been published yet that prospectively examined the effects of changing SRIs. This article describes the first double-blind switch study of 2 SRIs in @entity1 with @entity3119 . METHOD: 150 @entity1 with primary @entity3119 , according to DSM-IV criteria, were randomly assigned in a 12-week, double-blind trial to receive dosages titrated upward to 300 mg/day of @entity906 (N = 75) or 60 mg/day of @entity903 (N = 75). Primary efficacy was assessed by the change from baseline on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), and nonresponse was defined as less than 25% reduction on the Y-BOCS. After a 4-week tapering phase, 43 nonresponders were switched to 12 additional weeks of the alternate antidepressant, of which 16 @entity1 received @entity906 and 27 received @entity903 . RESULTS: Eighteen of 43 @entity1 benefited from a switch to the alternate @entity3595 with a mean +/- SD decrease of at least 25% on the Y-BOCS. At the end of 12 weeks, responder rates were 56% for @entity903 (15/27) and 19% for @entity906 (3/16). An intent-to-treat, last-observation-carried-forward analysis demonstrated a mean decrease on the Y-BOCS of 1.8 +/- 3.5 in the @entity906 group and 6.5 +/- 7.1 in the @entity903 group. After 2 consecutive @entity3595 trials, 109 of 150 @entity1 (73%) achieved a Y-BOCS decrease of at least 25%. CONCLUSION: The results of the current study show that 42% of the nonresponders benefited from a crossover to the other @entity3595 , and that @entity903 was more efficacious than @entity906 in the treatment of nonresponders to a previous @entity3595 trial. Switching SRIs in case of refractoriness may be considered a useful strategy for @entity1 with @entity3119 .
